Oxford BioDynamics - PDMR Dealing / Grant of Share Options

Oxford Biodynamics

10/11/2025 07:00

RNS Number : 8394G

Oxford BioDynamics PLC

10 November 2025

 

 

 

10 November 2025                                

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

PDMR Dealing / Grant of Share Options

Oxford BioDynamics Plc (AIM: OBD, the Company),  a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, announces that it has today granted a total of 170,000,000 options over its ordinary shares of 0.1 pence each ("Ordinary Shares"), to Group employees and advisers, including certain directors and PDMRs of the Company, as outlined in the table below.

The options were granted under the Company's 2016 Employee and Non-Employee Share Option Plans with an exercise price of 0.61p per share, representing a premium of 100% over the closing share price on 7 November 2025, the business day immediately preceding the grant of the options.

119,000,000 options granted to directors and PDMRs will vest monthly in 24 equal tranches to 10 November 2027.

51,000,000 options will vest in three tranches: 20% will vest immediately and will be exercisable from six months after the date of grant; 40% will vest and become exercisable on 10 November 2026; and 40% will vest and become exercisable on 10 November 2027.

Vested options will remain exercisable up to and including the tenth anniversary of the date of grant.

The grants made to directors and PDMRs of the Company were as follows:

New options granted
Total number of options over Ordinary Shares
Ordinary Shares held*
Number
% of current issued share capital
Iain Ross, Executive Chairman
44,000,000
140,000,000
23,333,333
0.54
Alexandre Akoulitchev, Chief Scientific Officer
15,000,000
34,596,131
14,228,962
0.33
David Blum, SVP of Marketing
15,000,000
33,462,500
744,611
0.02
Thomas Guiel, Chief Operations Officer
15,000,000
33,650,000
6,288,146
0.15
Ewan Hunter, Chief Data Officer
15,000,000
33,660,000
722,754
0.02
Paul Stockdale, Chief Financial Officer
15,000,000
33,980,000
6,411,252
0.15

*Shareholdings are stated following allotments pursuant to the recent fundraising. Percentages are calculated with reference to the Company's Enlarged Share Capital following General Admission, which is expected to take place on 11 November 2025.

The notifications below, made in accordance with the requirements of UK Market Abuse Regulation, provide further details:

1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Alexandre Akoulitchev
2
Reason for the notification
a)
Position/status
Director/PDMR
b)
Initial notification/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Oxford BioDynamics Plc
b)
LEI
2138005Y1TK258O5U928
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of 0.1 pence each
ISIN: GB00BD5H8572
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
15,000,000 ordinary shares at an exercise price of 0.61 pence per share
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
10 November 2025
f)
Place of the transaction
Outside a trading venue

 

 

 

 

1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
David Blum
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Oxford BioDynamics Plc
b)
LEI
2138005Y1TK258O5U928
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of 0.1 pence each
ISIN: GB00BD5H8572
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
15,000,000 ordinary shares at an exercise price of 0.61 pence per share
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
10 November 2025
f)
Place of the transaction
Outside a trading venue

 

 

 

1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Thomas Guiel
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Oxford BioDynamics Plc
b)
LEI
2138005Y1TK258O5U928
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of 0.1 pence each
ISIN: GB00BD5H8572
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
15,000,000 ordinary shares at an exercise price of 0.61 pence per share
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
10 November 2025
f)
Place of the transaction
Outside a trading venue

 

 

 

 

1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Ewan Hunter
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Oxford BioDynamics Plc
b)
LEI
2138005Y1TK258O5U928
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of 0.1 pence each
ISIN: GB00BD5H8572
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
15,000,000 ordinary shares at an exercise price of 0.61 pence per share
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
10 November 2025
f)
Place of the transaction
Outside a trading venue

 

 

 

 

1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Iain Ross
2
Reason for the notification
a)
Position/status
Director/PDMR
b)
Initial notification/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Oxford BioDynamics Plc
b)
LEI
2138005Y1TK258O5U928
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of 0.1 pence each
ISIN: GB00BD5H8572
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
44,000,000 ordinary shares at an exercise price of 0.61 pence per share
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
10 November 2025
f)
Place of the transaction
Outside a trading venue

 

 

 

1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Paul Stockdale
2
Reason for the notification
a)
Position/status
Director/PDMR
b)
Initial notification/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Oxford BioDynamics Plc
b)
LEI
2138005Y1TK258O5U928
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of 0.1 pence each
ISIN: GB00BD5H8572
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
15,000,000 ordinary shares at an exercise price of 0.61 pence per share
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Dates of the transactions
10 November 2025
f)
Place of the transaction
Outside a trading venue

 

 

 

-Ends-

For further details please contact:

Oxford BioDynamics Plc
Tel: +44 (0)1865 518910
Iain Ross, Executive Chairman
Paul Stockdale, CFO
Shore Capital - Nominated Adviser and Broker
Tel: +44 (0)20 7408 4090
Stephane Auton / Lucy Bowden
OAK Securities - Joint Broker
Tel: +44 (0)20 3973 3678
Matthew Clarke / Tim Dainton / Calvin Man
Camarco - Financial PR
Tel: +44 (0)20 3757 4980
Marc Cohen / Tilly Butcher / Fergus Young
OBDFinancial@camarco.co.uk

 

Notes to Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com,  X (@OxBioDynamics) or LinkedIn.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHKKLFBEFLXFBB